Drug intelligence / Profile preview

lactiplantibacillus plantarum CCFM8661

Development stage: Preclinical
Lead developer: Jiangnan University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactiplantibacillus plantarum CCFM8661 is a specific probiotic bacterial strain investigated for various health benefits. It is administered orally and primarily functions by modulating the gut microbiota. Research, including preclinical studies in mice and some human trials, indicates that CCFM8661 can enhance immune function, mitigate toxicity from environmental contaminants like heavy metals (e.g., lead) and pesticides (e.g., dichlorvos), protect against carcinogens like benzo[a]pyrene, and reduce signs of aging. Its mechanisms of action include restoring intestinal barrier function, reducing oxidative stress and inflammation, and altering the composition and metabolic output of the gut microbiome. The strain has been observed to bind directly to toxins, potentially aiding in their removal from the body. It is studied both as a single agent and in synbiotic combinations with other probiotics or prebiotics. The strain was isolated and is primarily researched by scientists at Jiangnan University in China.

Other names: L. plantarum CCFM8661

Beyond the preview

Go deeper on lactiplantibacillus plantarum CCFM8661.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactiplantibacillus plantarum CCFM8661.

Explore the full profile